Drug intelligence / Profile preview

Ga-68-NGUL + Lu-177-DGUL

Development stage: Unknown
Lead developer: Cellbion
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ga-68-NGUL + Lu-177-DGUL is a **combination of two radiopharmaceuticals** targeting prostate-specific membrane antigen (PSMA): **Ga-68-NGUL** is a PET imaging agent for the diagnosis of PSMA-expressing cancers, while **Lu-177-DGUL** is a therapeutic agent delivering beta radiation for targeted radioligand therapy. Both are based on Glu-Urea-Lys (GUL) derivatives—Ga-68-NGUL for imaging and Lu-177-DGUL for therapy—designed for sequential diagnostic and therapeutic (theranostic) use in patients with metastatic castration-resistant prostate cancer (mCRPC). Ga-68-NGUL allows precise PET-based localization of PSMA-positive lesions, and eligible patients identified by this scan may be treated with Lu-177-DGUL, which binds to PSMA and selectively irradiates cancer cells[1][2][3][7].

Other names: Ga-68-NGUL / Lu-177-DGUL68Ga-NGUL / 177Lu-DGUL68Ga-NGUL plus 177Lu-DGULPSMA-NGUL duo

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on Ga-68-NGUL + Lu-177-DGUL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ga-68-NGUL + Lu-177-DGUL.

Explore the full profile